{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:08:13Z","timestamp":1772838493331,"version":"3.50.1"},"reference-count":44,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,7,1]]},"DOI":"10.5551\/jat.63549","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T22:11:33Z","timestamp":1663366293000},"page":"767-777","source":"Crossref","is-referenced-by-count":3,"title":["Relationship between Serum Proprotein Convertase Subtilisin\/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men"],"prefix":"10.5551","volume":"30","author":[{"given":"Ayako","family":"Kunimura","sequence":"first","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"},{"name":"Department of Cardiology, Kobe Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"},{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Segawa","sequence":"additional","affiliation":[{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuki","family":"Torii","sequence":"additional","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"},{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"},{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujiyoshi","sequence":"additional","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"},{"name":"Department of Hygiene, Wakayama Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"},{"name":"Department of Cardiovascular Medicine, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Ueshima","sequence":"additional","affiliation":[{"name":"Department of Public Health, Shiga University of Medical Science"},{"name":"NCD Epidemiology Research Center, Shiga University of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Horton JD, Cohen JC and Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res, 2009; 50 Suppl: S172-7","DOI":"10.1194\/jlr.R800091-JLR200"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Stoekenbroek RM, Lambert G, Cariou B and Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol, 2018; 15: 52-62","DOI":"10.1038\/s41574-018-0110-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Seidah NG, Awan Z, Chr\u00e9tien M and Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res, 2014; 114: 1022-1036","DOI":"10.1161\/CIRCRESAHA.114.301621"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM and Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Jama, 2016; 316: 2373-2384","DOI":"10.1001\/jama.2016.16951"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD and Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Leander K, M\u00e4larstig A, Van\u2019t Hooft FM, Hyde C, Hell\u00e9nius ML, Troutt JS, Konrad RJ, \u00d6hrvik J, Hamsten A and de Faire U. Circulating Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. Circulation, 2016; 133: 1230-1239","DOI":"10.1161\/CIRCULATIONAHA.115.018531"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Laugsand LE, \u00c5svold BO, Vatten LJ, Janszky I, Platou CG, Michelsen AE, Dam\u00e5s JK, Aukrust P and Ueland T. Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway. JACC Basic Transl Sci, 2016; 1: 568-575","DOI":"10.1016\/j.jacbts.2016.06.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N, Stefanadis C and Tousoulis D. Prediction of cardiovascular events with levels of proprotein convertase subtilisin\/kexin type 9: A systematic review and meta-analysis. Atherosclerosis, 2016; 252: 50-60","DOI":"10.1016\/j.atherosclerosis.2016.07.922"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C and Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2021; 42: 3227-3337","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J, 2006; 70: 1249-1255","DOI":"10.1253\/circj.70.1249"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Gepner AD, Young R, Delaney JA, Tattersall MC, Blaha MJ, Post WS, Gottesman RF, Kronmal R, Budoff MJ, Burke GL, Folsom AR, Liu K, Kaufman J and Stein JH. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging, 2015; 8","DOI":"10.1161\/CIRCIMAGING.114.002262"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1046-e1081","DOI":"10.1161\/CIR.0000000000000624"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Sekikawa A, Kadota A, Kadowaki S, Nakamura Y, Miyagawa N, Okamura T, Kita Y, Takashima N, Kashiwagi A, Maegawa H, Horie M, Yamamoto T, Kimura T and Kita T. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis, 2016; 246: 141-147","DOI":"10.1016\/j.atherosclerosis.2015.12.027"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kadota A, Miura K, Okamura T, Fujiyoshi A, Ohkubo T, Kadowaki T, Takashima N, Hisamatsu T, Nakamura Y, Kasagi F, Maegawa H, Kashiwagi A and Ueshima H. Carotid intima-media thickness and plaque in apparently healthy Japanese individuals with an estimated 10-year absolute risk of CAD death according to the Japan Atherosclerosis Society (JAS) guidelines 2012: the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). J Atheroscler Thromb, 2013; 20: 755-766","DOI":"10.5551\/jat.17244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb, 2017; 24: 895-907","DOI":"10.5551\/jat.RV17012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Benjannet S, Rhainds D, Hamelin J, Nassoury N and Seidah NG. The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem, 2006; 281: 30561-30572","DOI":"10.1074\/jbc.M606495200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG and Prat A. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem, 2011; 286: 4257-4263","DOI":"10.1074\/jbc.M110.192104"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H and Harada-Shiba M. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. J Clin Endocrinol Metab, 2015; 100: E41-9","DOI":"10.1210\/jc.2014-3066"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kataoka Y, Harada-Shiba M, Nakao K, Nakashima T, Kawakami S, Fujino M, Kanaya T, Nagai T, Tahara Y, Asaumi Y, Hori M, Ogura M, Goto Y, Noguchi T and Yasuda S. Mature proprotein convertase subtilisin\/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. J Clin Lipidol, 2017; 11: 413-421.e3","DOI":"10.1016\/j.jacl.2017.01.005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr. and Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol, 1990; 15: 827-832","DOI":"10.1016\/0735-1097(90)90282-T"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Sekikawa A, Curb JD, Edmundowicz D, Okamura T, Choo J, Fujiyoshi A, Masaki K, Miura K, Kuller LH, Shin C and Ueshima H. Coronary artery calcification by computed tomography in epidemiologic research and cardiovascular disease prevention. J Epidemiol, 2012; 22: 188-198","DOI":"10.2188\/jea.JE20110138"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D, Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita Y and Kuller LH. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol, 2007; 165: 617-624","DOI":"10.1093\/aje\/kwk053"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, Abbott RD, Evans RW, Rodriguez BL, Okamura T, Sutton-Tyrrell K, Nakamura Y, Masaki K, Edmundowicz D, Kashiwagi A, Willcox BJ, Takamiya T, Mitsunami K, Seto TB, Murata K, White RL and Kuller LH. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol, 2008; 52: 417-424","DOI":"10.1016\/j.jacc.2008.03.047"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P and Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol, 2007; 49: 1860-1870","DOI":"10.1016\/j.jacc.2006.10.079"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol, 2004; 159: 702-706","DOI":"10.1093\/aje\/kwh090"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Alonso R, Mata P, Mu\u00f1iz O, Fuentes-Jimenez F, D\u00edaz JL, Zamb\u00f3n D, Tom\u00e1s M, Martin C, Moyon T, Croyal M, Thedrez A and Lambert G. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis, 2016; 254: 249-253","DOI":"10.1016\/j.atherosclerosis.2016.08.038"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lakoski SG, Lagace TA, Cohen JC, Horton JD and Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab, 2009; 94: 2537-2543","DOI":"10.1210\/jc.2009-0141"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX and Li JJ. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol, 2020; 19: 167","DOI":"10.1186\/s12933-020-01142-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M and Fukumoto Y. Serum Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. J Atheroscler Thromb, 2021; 28: 329-337","DOI":"10.5551\/jat.56390"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Hirata A, Kakino A, Okamura T, Usami Y, Fujita Y, Kadota A, Fujiyoshi A, Hisamatsu T, Kondo K, Segawa H, Sawamura T, Miura K and Ueshima H. The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men. Atherosclerosis, 2020; 313: 20-25","DOI":"10.1016\/j.atherosclerosis.2020.09.013"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Nagasawa SY, Okamura T, Iso H, Tamakoshi A, Yamada M, Watanabe M, Murakami Y, Miura K and Ueshima H. Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J Am Heart Assoc, 2012; 1: e001974","DOI":"10.1161\/JAHA.112.001974"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C and Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol, 2022; 29: 5-115","DOI":"10.1093\/eurjpc\/zwab154"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E and Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet, 2009; 2: 354-361","DOI":"10.1161\/CIRCGENETICS.108.828467"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Slimani A, Harira Y, Trabelsi I, Jomaa W, Maatouk F, Hamda KB and Slimane MN. Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort. J Mol Neurosci, 2014; 53: 150-157","DOI":"10.1007\/s12031-014-0238-2"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) T\u00f3th \u0160, Feda\u010dko J, Pek\u00e1rov\u00e1 T, Hertelyov\u00e1 Z, Katz M, Mughees A, Kuzma J, \u0160tefani\u010d P, Kopolovets I and Pella D. Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients. Cardiol Ther, 2017; 6: 281-289","DOI":"10.1007\/s40119-017-0092-8"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Xie W, Liu J, Wang W, Wang M, Qi Y, Zhao F, Sun J, Liu J, Li Y and Zhao D. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. Int J Cardiol, 2016; 215: 293-298","DOI":"10.1016\/j.ijcard.2016.04.103"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A and Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem, 2008; 283: 2363-2372","DOI":"10.1074\/jbc.M708098200"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM and Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol, 2014; 63: 2531-2540","DOI":"10.1016\/j.jacc.2014.03.018"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM and Stein EA. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. New Engl J Med, 2014; 370: 1809-1819","DOI":"10.1056\/NEJMoa1316222"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, DeLuca C, White CC, Cupples LA, McNamara JR, Seman LJ, Bongard V and Schaefer EJ. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res, 2011; 52: 1181-1187","DOI":"10.1194\/jlr.M012526"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN and Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol, 2014; 114: 711-715","DOI":"10.1016\/j.amjcard.2014.05.060"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kataoka Y, Harada-Shiba M, Hori M, Watanabe M, Kokubo Y, Noguchi T, Yasuda S and Miyamoto Y. Circulating Furin-Cleaved Proprotein Convertase Subtilisin\/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects. JACC: Asia, 2021; 1: 360-368","DOI":"10.1016\/j.jacasi.2021.09.003"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Furuhashi M, Kataoka Y, Nishikawa R, Koyama M, Sakai A, Higashiura Y, Tanaka M, Saitoh S, Shimamoto K and Ohnishi H. Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. J Atheroscler Thromb, 2022; 29: 1275-1284","DOI":"10.5551\/jat.63159"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/7\/30_63549\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:49:50Z","timestamp":1715316590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/7\/30_63549\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63549","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"article-number":"63549"}}